Global Transarterial Chemoembolization (TACE) Supply, Demand and Key Producers, 2023-2029
The global Transarterial Chemoembolization (TACE) market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
Trans-arterial Chemoembolization (TACE) is an interventional radiology procedure that delivers anti-cancer medication (chemotherapy) and embolizing materials directly into blood vessels feeding a malignant liver tumor. TACE is a two-pronged approach that can simultaneously limit the blood supply feeding a tumor in order to destroy cancerous cells (embolization) while the chemotherapy prevents further growth.Transarterial Chemoembolization (TACE) is a minimally invasive procedure in which chemotherapy and embolic agents are directly delivered to a cancerous tumour via its blood supply. The embolic agents are used to cut off the blood supply to the tumour without affecting the rest of the liver. Compared to receiving conventional chemotherapy, TACE allows for the maximum amount of chemotherapy agent to reach the tumour, while limiting the amount released into the bloodstream.
This report studies the global Transarterial Chemoembolization (TACE) demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Transarterial Chemoembolization (TACE), and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Transarterial Chemoembolization (TACE) that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Transarterial Chemoembolization (TACE) total market, 2018-2029, (USD Million)
Global Transarterial Chemoembolization (TACE) total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Transarterial Chemoembolization (TACE) total market, key domestic companies and share, (USD Million)
Global Transarterial Chemoembolization (TACE) revenue by player and market share 2018-2023, (USD Million)
Global Transarterial Chemoembolization (TACE) total market by Type, CAGR, 2018-2029, (USD Million)
Global Transarterial Chemoembolization (TACE) total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Transarterial Chemoembolization (TACE) market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Questex, Siemens Healthcare GmbH, Bellicum Pharmaceuticals Inc., Boston Scientific, Cook Group, Hikma Pharmaceuticals, Nippon Kayaku, Novartis AG and Pfizer Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Transarterial Chemoembolization (TACE) market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Transarterial Chemoembolization (TACE) Market, By Region:
1. How big is the global Transarterial Chemoembolization (TACE) market?
2. What is the demand of the global Transarterial Chemoembolization (TACE) market?
3. What is the year over year growth of the global Transarterial Chemoembolization (TACE) market?
4. What is the total value of the global Transarterial Chemoembolization (TACE) market?
5. Who are the major players in the global Transarterial Chemoembolization (TACE) market?
6. What are the growth factors driving the market demand?
Trans-arterial Chemoembolization (TACE) is an interventional radiology procedure that delivers anti-cancer medication (chemotherapy) and embolizing materials directly into blood vessels feeding a malignant liver tumor. TACE is a two-pronged approach that can simultaneously limit the blood supply feeding a tumor in order to destroy cancerous cells (embolization) while the chemotherapy prevents further growth.Transarterial Chemoembolization (TACE) is a minimally invasive procedure in which chemotherapy and embolic agents are directly delivered to a cancerous tumour via its blood supply. The embolic agents are used to cut off the blood supply to the tumour without affecting the rest of the liver. Compared to receiving conventional chemotherapy, TACE allows for the maximum amount of chemotherapy agent to reach the tumour, while limiting the amount released into the bloodstream.
This report studies the global Transarterial Chemoembolization (TACE) demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Transarterial Chemoembolization (TACE), and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Transarterial Chemoembolization (TACE) that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Transarterial Chemoembolization (TACE) total market, 2018-2029, (USD Million)
Global Transarterial Chemoembolization (TACE) total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Transarterial Chemoembolization (TACE) total market, key domestic companies and share, (USD Million)
Global Transarterial Chemoembolization (TACE) revenue by player and market share 2018-2023, (USD Million)
Global Transarterial Chemoembolization (TACE) total market by Type, CAGR, 2018-2029, (USD Million)
Global Transarterial Chemoembolization (TACE) total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Transarterial Chemoembolization (TACE) market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Questex, Siemens Healthcare GmbH, Bellicum Pharmaceuticals Inc., Boston Scientific, Cook Group, Hikma Pharmaceuticals, Nippon Kayaku, Novartis AG and Pfizer Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Transarterial Chemoembolization (TACE) market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Transarterial Chemoembolization (TACE) Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Chemotherapeutic Agents
- Radio Therapeutic Agents
- Drug-eluting Particles
- Others
- Hospitals
- Clinics
- Cancer Research Centers
- Questex
- Siemens Healthcare GmbH
- Bellicum Pharmaceuticals Inc.
- Boston Scientific
- Cook Group
- Hikma Pharmaceuticals
- Nippon Kayaku
- Novartis AG
- Pfizer Inc.
- Spectrum Pharmaceutical
- Roche Holding AG
- Celgene
- Bayer AG
- Merck & Co., Inc.
- SingHealth
1. How big is the global Transarterial Chemoembolization (TACE) market?
2. What is the demand of the global Transarterial Chemoembolization (TACE) market?
3. What is the year over year growth of the global Transarterial Chemoembolization (TACE) market?
4. What is the total value of the global Transarterial Chemoembolization (TACE) market?
5. Who are the major players in the global Transarterial Chemoembolization (TACE) market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Transarterial Chemoembolization (TACE) Introduction
1.2 World Transarterial Chemoembolization (TACE) Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Transarterial Chemoembolization (TACE) Total Market by Region (by Headquarter Location)
1.3.1 World Transarterial Chemoembolization (TACE) Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.3.3 China Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.3.4 Europe Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.3.5 Japan Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.3.6 South Korea Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.3.7 ASEAN Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.3.8 India Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Transarterial Chemoembolization (TACE) Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Transarterial Chemoembolization (TACE) Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.2 World Transarterial Chemoembolization (TACE) Consumption Value by Region
2.2.1 World Transarterial Chemoembolization (TACE) Consumption Value by Region (2018-2023)
2.2.2 World Transarterial Chemoembolization (TACE) Consumption Value Forecast by Region (2024-2029)
2.3 United States Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.4 China Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.5 Europe Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.6 Japan Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.7 South Korea Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.8 ASEAN Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.9 India Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
3 WORLD TRANSARTERIAL CHEMOEMBOLIZATION (TACE) COMPANIES COMPETITIVE ANALYSIS
3.1 World Transarterial Chemoembolization (TACE) Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Transarterial Chemoembolization (TACE) Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Transarterial Chemoembolization (TACE) in 2022
3.2.3 Global Concentration Ratios (CR8) for Transarterial Chemoembolization (TACE) in 2022
3.3 Transarterial Chemoembolization (TACE) Company Evaluation Quadrant
3.4 Transarterial Chemoembolization (TACE) Market: Overall Company Footprint Analysis
3.4.1 Transarterial Chemoembolization (TACE) Market: Region Footprint
3.4.2 Transarterial Chemoembolization (TACE) Market: Company Product Type Footprint
3.4.3 Transarterial Chemoembolization (TACE) Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Transarterial Chemoembolization (TACE) Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Transarterial Chemoembolization (TACE) Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Transarterial Chemoembolization (TACE) Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Transarterial Chemoembolization (TACE) Consumption Value Comparison
4.2.1 United States VS China: Transarterial Chemoembolization (TACE) Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Transarterial Chemoembolization (TACE) Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Transarterial Chemoembolization (TACE) Companies and Market Share, 2018-2023
4.3.1 United States Based Transarterial Chemoembolization (TACE) Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Transarterial Chemoembolization (TACE) Revenue, (2018-2023)
4.4 China Based Companies Transarterial Chemoembolization (TACE) Revenue and Market Share, 2018-2023
4.4.1 China Based Transarterial Chemoembolization (TACE) Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Transarterial Chemoembolization (TACE) Revenue, (2018-2023)
4.5 Rest of World Based Transarterial Chemoembolization (TACE) Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Transarterial Chemoembolization (TACE) Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Transarterial Chemoembolization (TACE) Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Transarterial Chemoembolization (TACE) Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Chemotherapeutic Agents
5.2.2 Radio Therapeutic Agents
5.2.3 Drug-eluting Particles
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Transarterial Chemoembolization (TACE) Market Size by Type (2018-2023)
5.3.2 World Transarterial Chemoembolization (TACE) Market Size by Type (2024-2029)
5.3.3 World Transarterial Chemoembolization (TACE) Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Transarterial Chemoembolization (TACE) Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Cancer Research Centers
6.3 Market Segment by Application
6.3.1 World Transarterial Chemoembolization (TACE) Market Size by Application (2018-2023)
6.3.2 World Transarterial Chemoembolization (TACE) Market Size by Application (2024-2029)
6.3.3 World Transarterial Chemoembolization (TACE) Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Questex
7.1.1 Questex Details
7.1.2 Questex Major Business
7.1.3 Questex Transarterial Chemoembolization (TACE) Product and Services
7.1.4 Questex Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Questex Recent Developments/Updates
7.1.6 Questex Competitive Strengths & Weaknesses
7.2 Siemens Healthcare GmbH
7.2.1 Siemens Healthcare GmbH Details
7.2.2 Siemens Healthcare GmbH Major Business
7.2.3 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Product and Services
7.2.4 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Siemens Healthcare GmbH Recent Developments/Updates
7.2.6 Siemens Healthcare GmbH Competitive Strengths & Weaknesses
7.3 Bellicum Pharmaceuticals Inc.
7.3.1 Bellicum Pharmaceuticals Inc. Details
7.3.2 Bellicum Pharmaceuticals Inc. Major Business
7.3.3 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Product and Services
7.3.4 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Bellicum Pharmaceuticals Inc. Recent Developments/Updates
7.3.6 Bellicum Pharmaceuticals Inc. Competitive Strengths & Weaknesses
7.4 Boston Scientific
7.4.1 Boston Scientific Details
7.4.2 Boston Scientific Major Business
7.4.3 Boston Scientific Transarterial Chemoembolization (TACE) Product and Services
7.4.4 Boston Scientific Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Boston Scientific Recent Developments/Updates
7.4.6 Boston Scientific Competitive Strengths & Weaknesses
7.5 Cook Group
7.5.1 Cook Group Details
7.5.2 Cook Group Major Business
7.5.3 Cook Group Transarterial Chemoembolization (TACE) Product and Services
7.5.4 Cook Group Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Cook Group Recent Developments/Updates
7.5.6 Cook Group Competitive Strengths & Weaknesses
7.6 Hikma Pharmaceuticals
7.6.1 Hikma Pharmaceuticals Details
7.6.2 Hikma Pharmaceuticals Major Business
7.6.3 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Product and Services
7.6.4 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Hikma Pharmaceuticals Recent Developments/Updates
7.6.6 Hikma Pharmaceuticals Competitive Strengths & Weaknesses
7.7 Nippon Kayaku
7.7.1 Nippon Kayaku Details
7.7.2 Nippon Kayaku Major Business
7.7.3 Nippon Kayaku Transarterial Chemoembolization (TACE) Product and Services
7.7.4 Nippon Kayaku Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Nippon Kayaku Recent Developments/Updates
7.7.6 Nippon Kayaku Competitive Strengths & Weaknesses
7.8 Novartis AG
7.8.1 Novartis AG Details
7.8.2 Novartis AG Major Business
7.8.3 Novartis AG Transarterial Chemoembolization (TACE) Product and Services
7.8.4 Novartis AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Novartis AG Recent Developments/Updates
7.8.6 Novartis AG Competitive Strengths & Weaknesses
7.9 Pfizer Inc.
7.9.1 Pfizer Inc. Details
7.9.2 Pfizer Inc. Major Business
7.9.3 Pfizer Inc. Transarterial Chemoembolization (TACE) Product and Services
7.9.4 Pfizer Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Pfizer Inc. Recent Developments/Updates
7.9.6 Pfizer Inc. Competitive Strengths & Weaknesses
7.10 Spectrum Pharmaceutical
7.10.1 Spectrum Pharmaceutical Details
7.10.2 Spectrum Pharmaceutical Major Business
7.10.3 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Product and Services
7.10.4 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Spectrum Pharmaceutical Recent Developments/Updates
7.10.6 Spectrum Pharmaceutical Competitive Strengths & Weaknesses
7.11 Roche Holding AG
7.11.1 Roche Holding AG Details
7.11.2 Roche Holding AG Major Business
7.11.3 Roche Holding AG Transarterial Chemoembolization (TACE) Product and Services
7.11.4 Roche Holding AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Roche Holding AG Recent Developments/Updates
7.11.6 Roche Holding AG Competitive Strengths & Weaknesses
7.12 Celgene
7.12.1 Celgene Details
7.12.2 Celgene Major Business
7.12.3 Celgene Transarterial Chemoembolization (TACE) Product and Services
7.12.4 Celgene Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Celgene Recent Developments/Updates
7.12.6 Celgene Competitive Strengths & Weaknesses
7.13 Bayer AG
7.13.1 Bayer AG Details
7.13.2 Bayer AG Major Business
7.13.3 Bayer AG Transarterial Chemoembolization (TACE) Product and Services
7.13.4 Bayer AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Bayer AG Recent Developments/Updates
7.13.6 Bayer AG Competitive Strengths & Weaknesses
7.14 Merck & Co., Inc.
7.14.1 Merck & Co., Inc. Details
7.14.2 Merck & Co., Inc. Major Business
7.14.3 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Product and Services
7.14.4 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Merck & Co., Inc. Recent Developments/Updates
7.14.6 Merck & Co., Inc. Competitive Strengths & Weaknesses
7.15 SingHealth
7.15.1 SingHealth Details
7.15.2 SingHealth Major Business
7.15.3 SingHealth Transarterial Chemoembolization (TACE) Product and Services
7.15.4 SingHealth Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 SingHealth Recent Developments/Updates
7.15.6 SingHealth Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Transarterial Chemoembolization (TACE) Industry Chain
8.2 Transarterial Chemoembolization (TACE) Upstream Analysis
8.3 Transarterial Chemoembolization (TACE) Midstream Analysis
8.4 Transarterial Chemoembolization (TACE) Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Transarterial Chemoembolization (TACE) Introduction
1.2 World Transarterial Chemoembolization (TACE) Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Transarterial Chemoembolization (TACE) Total Market by Region (by Headquarter Location)
1.3.1 World Transarterial Chemoembolization (TACE) Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.3.3 China Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.3.4 Europe Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.3.5 Japan Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.3.6 South Korea Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.3.7 ASEAN Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.3.8 India Transarterial Chemoembolization (TACE) Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Transarterial Chemoembolization (TACE) Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Transarterial Chemoembolization (TACE) Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.2 World Transarterial Chemoembolization (TACE) Consumption Value by Region
2.2.1 World Transarterial Chemoembolization (TACE) Consumption Value by Region (2018-2023)
2.2.2 World Transarterial Chemoembolization (TACE) Consumption Value Forecast by Region (2024-2029)
2.3 United States Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.4 China Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.5 Europe Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.6 Japan Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.7 South Korea Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.8 ASEAN Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
2.9 India Transarterial Chemoembolization (TACE) Consumption Value (2018-2029)
3 WORLD TRANSARTERIAL CHEMOEMBOLIZATION (TACE) COMPANIES COMPETITIVE ANALYSIS
3.1 World Transarterial Chemoembolization (TACE) Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Transarterial Chemoembolization (TACE) Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Transarterial Chemoembolization (TACE) in 2022
3.2.3 Global Concentration Ratios (CR8) for Transarterial Chemoembolization (TACE) in 2022
3.3 Transarterial Chemoembolization (TACE) Company Evaluation Quadrant
3.4 Transarterial Chemoembolization (TACE) Market: Overall Company Footprint Analysis
3.4.1 Transarterial Chemoembolization (TACE) Market: Region Footprint
3.4.2 Transarterial Chemoembolization (TACE) Market: Company Product Type Footprint
3.4.3 Transarterial Chemoembolization (TACE) Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Transarterial Chemoembolization (TACE) Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Transarterial Chemoembolization (TACE) Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Transarterial Chemoembolization (TACE) Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Transarterial Chemoembolization (TACE) Consumption Value Comparison
4.2.1 United States VS China: Transarterial Chemoembolization (TACE) Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Transarterial Chemoembolization (TACE) Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Transarterial Chemoembolization (TACE) Companies and Market Share, 2018-2023
4.3.1 United States Based Transarterial Chemoembolization (TACE) Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Transarterial Chemoembolization (TACE) Revenue, (2018-2023)
4.4 China Based Companies Transarterial Chemoembolization (TACE) Revenue and Market Share, 2018-2023
4.4.1 China Based Transarterial Chemoembolization (TACE) Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Transarterial Chemoembolization (TACE) Revenue, (2018-2023)
4.5 Rest of World Based Transarterial Chemoembolization (TACE) Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Transarterial Chemoembolization (TACE) Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Transarterial Chemoembolization (TACE) Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Transarterial Chemoembolization (TACE) Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Chemotherapeutic Agents
5.2.2 Radio Therapeutic Agents
5.2.3 Drug-eluting Particles
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Transarterial Chemoembolization (TACE) Market Size by Type (2018-2023)
5.3.2 World Transarterial Chemoembolization (TACE) Market Size by Type (2024-2029)
5.3.3 World Transarterial Chemoembolization (TACE) Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Transarterial Chemoembolization (TACE) Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Cancer Research Centers
6.3 Market Segment by Application
6.3.1 World Transarterial Chemoembolization (TACE) Market Size by Application (2018-2023)
6.3.2 World Transarterial Chemoembolization (TACE) Market Size by Application (2024-2029)
6.3.3 World Transarterial Chemoembolization (TACE) Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Questex
7.1.1 Questex Details
7.1.2 Questex Major Business
7.1.3 Questex Transarterial Chemoembolization (TACE) Product and Services
7.1.4 Questex Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Questex Recent Developments/Updates
7.1.6 Questex Competitive Strengths & Weaknesses
7.2 Siemens Healthcare GmbH
7.2.1 Siemens Healthcare GmbH Details
7.2.2 Siemens Healthcare GmbH Major Business
7.2.3 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Product and Services
7.2.4 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Siemens Healthcare GmbH Recent Developments/Updates
7.2.6 Siemens Healthcare GmbH Competitive Strengths & Weaknesses
7.3 Bellicum Pharmaceuticals Inc.
7.3.1 Bellicum Pharmaceuticals Inc. Details
7.3.2 Bellicum Pharmaceuticals Inc. Major Business
7.3.3 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Product and Services
7.3.4 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Bellicum Pharmaceuticals Inc. Recent Developments/Updates
7.3.6 Bellicum Pharmaceuticals Inc. Competitive Strengths & Weaknesses
7.4 Boston Scientific
7.4.1 Boston Scientific Details
7.4.2 Boston Scientific Major Business
7.4.3 Boston Scientific Transarterial Chemoembolization (TACE) Product and Services
7.4.4 Boston Scientific Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Boston Scientific Recent Developments/Updates
7.4.6 Boston Scientific Competitive Strengths & Weaknesses
7.5 Cook Group
7.5.1 Cook Group Details
7.5.2 Cook Group Major Business
7.5.3 Cook Group Transarterial Chemoembolization (TACE) Product and Services
7.5.4 Cook Group Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Cook Group Recent Developments/Updates
7.5.6 Cook Group Competitive Strengths & Weaknesses
7.6 Hikma Pharmaceuticals
7.6.1 Hikma Pharmaceuticals Details
7.6.2 Hikma Pharmaceuticals Major Business
7.6.3 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Product and Services
7.6.4 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Hikma Pharmaceuticals Recent Developments/Updates
7.6.6 Hikma Pharmaceuticals Competitive Strengths & Weaknesses
7.7 Nippon Kayaku
7.7.1 Nippon Kayaku Details
7.7.2 Nippon Kayaku Major Business
7.7.3 Nippon Kayaku Transarterial Chemoembolization (TACE) Product and Services
7.7.4 Nippon Kayaku Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Nippon Kayaku Recent Developments/Updates
7.7.6 Nippon Kayaku Competitive Strengths & Weaknesses
7.8 Novartis AG
7.8.1 Novartis AG Details
7.8.2 Novartis AG Major Business
7.8.3 Novartis AG Transarterial Chemoembolization (TACE) Product and Services
7.8.4 Novartis AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Novartis AG Recent Developments/Updates
7.8.6 Novartis AG Competitive Strengths & Weaknesses
7.9 Pfizer Inc.
7.9.1 Pfizer Inc. Details
7.9.2 Pfizer Inc. Major Business
7.9.3 Pfizer Inc. Transarterial Chemoembolization (TACE) Product and Services
7.9.4 Pfizer Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Pfizer Inc. Recent Developments/Updates
7.9.6 Pfizer Inc. Competitive Strengths & Weaknesses
7.10 Spectrum Pharmaceutical
7.10.1 Spectrum Pharmaceutical Details
7.10.2 Spectrum Pharmaceutical Major Business
7.10.3 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Product and Services
7.10.4 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Spectrum Pharmaceutical Recent Developments/Updates
7.10.6 Spectrum Pharmaceutical Competitive Strengths & Weaknesses
7.11 Roche Holding AG
7.11.1 Roche Holding AG Details
7.11.2 Roche Holding AG Major Business
7.11.3 Roche Holding AG Transarterial Chemoembolization (TACE) Product and Services
7.11.4 Roche Holding AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Roche Holding AG Recent Developments/Updates
7.11.6 Roche Holding AG Competitive Strengths & Weaknesses
7.12 Celgene
7.12.1 Celgene Details
7.12.2 Celgene Major Business
7.12.3 Celgene Transarterial Chemoembolization (TACE) Product and Services
7.12.4 Celgene Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Celgene Recent Developments/Updates
7.12.6 Celgene Competitive Strengths & Weaknesses
7.13 Bayer AG
7.13.1 Bayer AG Details
7.13.2 Bayer AG Major Business
7.13.3 Bayer AG Transarterial Chemoembolization (TACE) Product and Services
7.13.4 Bayer AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Bayer AG Recent Developments/Updates
7.13.6 Bayer AG Competitive Strengths & Weaknesses
7.14 Merck & Co., Inc.
7.14.1 Merck & Co., Inc. Details
7.14.2 Merck & Co., Inc. Major Business
7.14.3 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Product and Services
7.14.4 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Merck & Co., Inc. Recent Developments/Updates
7.14.6 Merck & Co., Inc. Competitive Strengths & Weaknesses
7.15 SingHealth
7.15.1 SingHealth Details
7.15.2 SingHealth Major Business
7.15.3 SingHealth Transarterial Chemoembolization (TACE) Product and Services
7.15.4 SingHealth Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 SingHealth Recent Developments/Updates
7.15.6 SingHealth Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Transarterial Chemoembolization (TACE) Industry Chain
8.2 Transarterial Chemoembolization (TACE) Upstream Analysis
8.3 Transarterial Chemoembolization (TACE) Midstream Analysis
8.4 Transarterial Chemoembolization (TACE) Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Transarterial Chemoembolization (TACE) Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Transarterial Chemoembolization (TACE) Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Transarterial Chemoembolization (TACE) Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Transarterial Chemoembolization (TACE) Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Transarterial Chemoembolization (TACE) Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Transarterial Chemoembolization (TACE) Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Transarterial Chemoembolization (TACE) Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Transarterial Chemoembolization (TACE) Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Transarterial Chemoembolization (TACE) Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Transarterial Chemoembolization (TACE) Players in 2022
Table 12. World Transarterial Chemoembolization (TACE) Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Transarterial Chemoembolization (TACE) Company Evaluation Quadrant
Table 14. Head Office of Key Transarterial Chemoembolization (TACE) Player
Table 15. Transarterial Chemoembolization (TACE) Market: Company Product Type Footprint
Table 16. Transarterial Chemoembolization (TACE) Market: Company Product Application Footprint
Table 17. Transarterial Chemoembolization (TACE) Mergers & Acquisitions Activity
Table 18. United States VS China Transarterial Chemoembolization (TACE) Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Transarterial Chemoembolization (TACE) Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Transarterial Chemoembolization (TACE) Companies, Headquarters (States, Country)
Table 21. United States Based Companies Transarterial Chemoembolization (TACE) Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Transarterial Chemoembolization (TACE) Revenue Market Share (2018-2023)
Table 23. China Based Transarterial Chemoembolization (TACE) Companies, Headquarters (Province, Country)
Table 24. China Based Companies Transarterial Chemoembolization (TACE) Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Transarterial Chemoembolization (TACE) Revenue Market Share (2018-2023)
Table 26. Rest of World Based Transarterial Chemoembolization (TACE) Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Transarterial Chemoembolization (TACE) Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Transarterial Chemoembolization (TACE) Revenue Market Share (2018-2023)
Table 29. World Transarterial Chemoembolization (TACE) Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Transarterial Chemoembolization (TACE) Market Size by Type (2018-2023) & (USD Million)
Table 31. World Transarterial Chemoembolization (TACE) Market Size by Type (2024-2029) & (USD Million)
Table 32. World Transarterial Chemoembolization (TACE) Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Transarterial Chemoembolization (TACE) Market Size by Application (2018-2023) & (USD Million)
Table 34. World Transarterial Chemoembolization (TACE) Market Size by Application (2024-2029) & (USD Million)
Table 35. Questex Basic Information, Area Served and Competitors
Table 36. Questex Major Business
Table 37. Questex Transarterial Chemoembolization (TACE) Product and Services
Table 38. Questex Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Questex Recent Developments/Updates
Table 40. Questex Competitive Strengths & Weaknesses
Table 41. Siemens Healthcare GmbH Basic Information, Area Served and Competitors
Table 42. Siemens Healthcare GmbH Major Business
Table 43. Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Product and Services
Table 44. Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Siemens Healthcare GmbH Recent Developments/Updates
Table 46. Siemens Healthcare GmbH Competitive Strengths & Weaknesses
Table 47. Bellicum Pharmaceuticals Inc. Basic Information, Area Served and Competitors
Table 48. Bellicum Pharmaceuticals Inc. Major Business
Table 49. Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Product and Services
Table 50. Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Bellicum Pharmaceuticals Inc. Recent Developments/Updates
Table 52. Bellicum Pharmaceuticals Inc. Competitive Strengths & Weaknesses
Table 53. Boston Scientific Basic Information, Area Served and Competitors
Table 54. Boston Scientific Major Business
Table 55. Boston Scientific Transarterial Chemoembolization (TACE) Product and Services
Table 56. Boston Scientific Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Boston Scientific Recent Developments/Updates
Table 58. Boston Scientific Competitive Strengths & Weaknesses
Table 59. Cook Group Basic Information, Area Served and Competitors
Table 60. Cook Group Major Business
Table 61. Cook Group Transarterial Chemoembolization (TACE) Product and Services
Table 62. Cook Group Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Cook Group Recent Developments/Updates
Table 64. Cook Group Competitive Strengths & Weaknesses
Table 65. Hikma Pharmaceuticals Basic Information, Area Served and Competitors
Table 66. Hikma Pharmaceuticals Major Business
Table 67. Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Product and Services
Table 68. Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Hikma Pharmaceuticals Recent Developments/Updates
Table 70. Hikma Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Nippon Kayaku Basic Information, Area Served and Competitors
Table 72. Nippon Kayaku Major Business
Table 73. Nippon Kayaku Transarterial Chemoembolization (TACE) Product and Services
Table 74. Nippon Kayaku Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Nippon Kayaku Recent Developments/Updates
Table 76. Nippon Kayaku Competitive Strengths & Weaknesses
Table 77. Novartis AG Basic Information, Area Served and Competitors
Table 78. Novartis AG Major Business
Table 79. Novartis AG Transarterial Chemoembolization (TACE) Product and Services
Table 80. Novartis AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Novartis AG Recent Developments/Updates
Table 82. Novartis AG Competitive Strengths & Weaknesses
Table 83. Pfizer Inc. Basic Information, Area Served and Competitors
Table 84. Pfizer Inc. Major Business
Table 85. Pfizer Inc. Transarterial Chemoembolization (TACE) Product and Services
Table 86. Pfizer Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Pfizer Inc. Recent Developments/Updates
Table 88. Pfizer Inc. Competitive Strengths & Weaknesses
Table 89. Spectrum Pharmaceutical Basic Information, Area Served and Competitors
Table 90. Spectrum Pharmaceutical Major Business
Table 91. Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Product and Services
Table 92. Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Spectrum Pharmaceutical Recent Developments/Updates
Table 94. Spectrum Pharmaceutical Competitive Strengths & Weaknesses
Table 95. Roche Holding AG Basic Information, Area Served and Competitors
Table 96. Roche Holding AG Major Business
Table 97. Roche Holding AG Transarterial Chemoembolization (TACE) Product and Services
Table 98. Roche Holding AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Roche Holding AG Recent Developments/Updates
Table 100. Roche Holding AG Competitive Strengths & Weaknesses
Table 101. Celgene Basic Information, Area Served and Competitors
Table 102. Celgene Major Business
Table 103. Celgene Transarterial Chemoembolization (TACE) Product and Services
Table 104. Celgene Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Celgene Recent Developments/Updates
Table 106. Celgene Competitive Strengths & Weaknesses
Table 107. Bayer AG Basic Information, Area Served and Competitors
Table 108. Bayer AG Major Business
Table 109. Bayer AG Transarterial Chemoembolization (TACE) Product and Services
Table 110. Bayer AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Bayer AG Recent Developments/Updates
Table 112. Bayer AG Competitive Strengths & Weaknesses
Table 113. Merck & Co., Inc. Basic Information, Area Served and Competitors
Table 114. Merck & Co., Inc. Major Business
Table 115. Merck & Co., Inc. Transarterial Chemoembolization (TACE) Product and Services
Table 116. Merck & Co., Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Merck & Co., Inc. Recent Developments/Updates
Table 118. SingHealth Basic Information, Area Served and Competitors
Table 119. SingHealth Major Business
Table 120. SingHealth Transarterial Chemoembolization (TACE) Product and Services
Table 121. SingHealth Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 122. Global Key Players of Transarterial Chemoembolization (TACE) Upstream (Raw Materials)
Table 123. Transarterial Chemoembolization (TACE) Typical Customers
Table 1. World Transarterial Chemoembolization (TACE) Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Transarterial Chemoembolization (TACE) Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Transarterial Chemoembolization (TACE) Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Transarterial Chemoembolization (TACE) Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Transarterial Chemoembolization (TACE) Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Transarterial Chemoembolization (TACE) Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Transarterial Chemoembolization (TACE) Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Transarterial Chemoembolization (TACE) Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Transarterial Chemoembolization (TACE) Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Transarterial Chemoembolization (TACE) Players in 2022
Table 12. World Transarterial Chemoembolization (TACE) Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Transarterial Chemoembolization (TACE) Company Evaluation Quadrant
Table 14. Head Office of Key Transarterial Chemoembolization (TACE) Player
Table 15. Transarterial Chemoembolization (TACE) Market: Company Product Type Footprint
Table 16. Transarterial Chemoembolization (TACE) Market: Company Product Application Footprint
Table 17. Transarterial Chemoembolization (TACE) Mergers & Acquisitions Activity
Table 18. United States VS China Transarterial Chemoembolization (TACE) Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Transarterial Chemoembolization (TACE) Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Transarterial Chemoembolization (TACE) Companies, Headquarters (States, Country)
Table 21. United States Based Companies Transarterial Chemoembolization (TACE) Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Transarterial Chemoembolization (TACE) Revenue Market Share (2018-2023)
Table 23. China Based Transarterial Chemoembolization (TACE) Companies, Headquarters (Province, Country)
Table 24. China Based Companies Transarterial Chemoembolization (TACE) Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Transarterial Chemoembolization (TACE) Revenue Market Share (2018-2023)
Table 26. Rest of World Based Transarterial Chemoembolization (TACE) Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Transarterial Chemoembolization (TACE) Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Transarterial Chemoembolization (TACE) Revenue Market Share (2018-2023)
Table 29. World Transarterial Chemoembolization (TACE) Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Transarterial Chemoembolization (TACE) Market Size by Type (2018-2023) & (USD Million)
Table 31. World Transarterial Chemoembolization (TACE) Market Size by Type (2024-2029) & (USD Million)
Table 32. World Transarterial Chemoembolization (TACE) Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Transarterial Chemoembolization (TACE) Market Size by Application (2018-2023) & (USD Million)
Table 34. World Transarterial Chemoembolization (TACE) Market Size by Application (2024-2029) & (USD Million)
Table 35. Questex Basic Information, Area Served and Competitors
Table 36. Questex Major Business
Table 37. Questex Transarterial Chemoembolization (TACE) Product and Services
Table 38. Questex Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Questex Recent Developments/Updates
Table 40. Questex Competitive Strengths & Weaknesses
Table 41. Siemens Healthcare GmbH Basic Information, Area Served and Competitors
Table 42. Siemens Healthcare GmbH Major Business
Table 43. Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Product and Services
Table 44. Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Siemens Healthcare GmbH Recent Developments/Updates
Table 46. Siemens Healthcare GmbH Competitive Strengths & Weaknesses
Table 47. Bellicum Pharmaceuticals Inc. Basic Information, Area Served and Competitors
Table 48. Bellicum Pharmaceuticals Inc. Major Business
Table 49. Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Product and Services
Table 50. Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Bellicum Pharmaceuticals Inc. Recent Developments/Updates
Table 52. Bellicum Pharmaceuticals Inc. Competitive Strengths & Weaknesses
Table 53. Boston Scientific Basic Information, Area Served and Competitors
Table 54. Boston Scientific Major Business
Table 55. Boston Scientific Transarterial Chemoembolization (TACE) Product and Services
Table 56. Boston Scientific Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Boston Scientific Recent Developments/Updates
Table 58. Boston Scientific Competitive Strengths & Weaknesses
Table 59. Cook Group Basic Information, Area Served and Competitors
Table 60. Cook Group Major Business
Table 61. Cook Group Transarterial Chemoembolization (TACE) Product and Services
Table 62. Cook Group Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Cook Group Recent Developments/Updates
Table 64. Cook Group Competitive Strengths & Weaknesses
Table 65. Hikma Pharmaceuticals Basic Information, Area Served and Competitors
Table 66. Hikma Pharmaceuticals Major Business
Table 67. Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Product and Services
Table 68. Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Hikma Pharmaceuticals Recent Developments/Updates
Table 70. Hikma Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Nippon Kayaku Basic Information, Area Served and Competitors
Table 72. Nippon Kayaku Major Business
Table 73. Nippon Kayaku Transarterial Chemoembolization (TACE) Product and Services
Table 74. Nippon Kayaku Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Nippon Kayaku Recent Developments/Updates
Table 76. Nippon Kayaku Competitive Strengths & Weaknesses
Table 77. Novartis AG Basic Information, Area Served and Competitors
Table 78. Novartis AG Major Business
Table 79. Novartis AG Transarterial Chemoembolization (TACE) Product and Services
Table 80. Novartis AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Novartis AG Recent Developments/Updates
Table 82. Novartis AG Competitive Strengths & Weaknesses
Table 83. Pfizer Inc. Basic Information, Area Served and Competitors
Table 84. Pfizer Inc. Major Business
Table 85. Pfizer Inc. Transarterial Chemoembolization (TACE) Product and Services
Table 86. Pfizer Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Pfizer Inc. Recent Developments/Updates
Table 88. Pfizer Inc. Competitive Strengths & Weaknesses
Table 89. Spectrum Pharmaceutical Basic Information, Area Served and Competitors
Table 90. Spectrum Pharmaceutical Major Business
Table 91. Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Product and Services
Table 92. Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Spectrum Pharmaceutical Recent Developments/Updates
Table 94. Spectrum Pharmaceutical Competitive Strengths & Weaknesses
Table 95. Roche Holding AG Basic Information, Area Served and Competitors
Table 96. Roche Holding AG Major Business
Table 97. Roche Holding AG Transarterial Chemoembolization (TACE) Product and Services
Table 98. Roche Holding AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Roche Holding AG Recent Developments/Updates
Table 100. Roche Holding AG Competitive Strengths & Weaknesses
Table 101. Celgene Basic Information, Area Served and Competitors
Table 102. Celgene Major Business
Table 103. Celgene Transarterial Chemoembolization (TACE) Product and Services
Table 104. Celgene Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Celgene Recent Developments/Updates
Table 106. Celgene Competitive Strengths & Weaknesses
Table 107. Bayer AG Basic Information, Area Served and Competitors
Table 108. Bayer AG Major Business
Table 109. Bayer AG Transarterial Chemoembolization (TACE) Product and Services
Table 110. Bayer AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Bayer AG Recent Developments/Updates
Table 112. Bayer AG Competitive Strengths & Weaknesses
Table 113. Merck & Co., Inc. Basic Information, Area Served and Competitors
Table 114. Merck & Co., Inc. Major Business
Table 115. Merck & Co., Inc. Transarterial Chemoembolization (TACE) Product and Services
Table 116. Merck & Co., Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Merck & Co., Inc. Recent Developments/Updates
Table 118. SingHealth Basic Information, Area Served and Competitors
Table 119. SingHealth Major Business
Table 120. SingHealth Transarterial Chemoembolization (TACE) Product and Services
Table 121. SingHealth Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 122. Global Key Players of Transarterial Chemoembolization (TACE) Upstream (Raw Materials)
Table 123. Transarterial Chemoembolization (TACE) Typical Customers
LIST OF FIGURES
Figure 1. Transarterial Chemoembolization (TACE) Picture
Figure 2. World Transarterial Chemoembolization (TACE) Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Transarterial Chemoembolization (TACE) Total Market Size (2018-2029) & (USD Million)
Figure 4. World Transarterial Chemoembolization (TACE) Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Transarterial Chemoembolization (TACE) Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 13. Transarterial Chemoembolization (TACE) Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 16. World Transarterial Chemoembolization (TACE) Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 18. China Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 23. India Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Transarterial Chemoembolization (TACE) by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Transarterial Chemoembolization (TACE) Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Transarterial Chemoembolization (TACE) Markets in 2022
Figure 27. United States VS China: Transarterial Chemoembolization (TACE) Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Transarterial Chemoembolization (TACE) Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Transarterial Chemoembolization (TACE) Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Transarterial Chemoembolization (TACE) Market Size Market Share by Type in 2022
Figure 31. Chemotherapeutic Agents
Figure 32. Radio Therapeutic Agents
Figure 33. Drug-eluting Particles
Figure 34. Others
Figure 35. World Transarterial Chemoembolization (TACE) Market Size Market Share by Type (2018-2029)
Figure 36. World Transarterial Chemoembolization (TACE) Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 37. World Transarterial Chemoembolization (TACE) Market Size Market Share by Application in 2022
Figure 38. Hospitals
Figure 39. Clinics
Figure 40. Cancer Research Centers
Figure 41. Transarterial Chemoembolization (TACE) Industrial Chain
Figure 42. Methodology
Figure 43. Research Process and Data Source
Figure 1. Transarterial Chemoembolization (TACE) Picture
Figure 2. World Transarterial Chemoembolization (TACE) Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Transarterial Chemoembolization (TACE) Total Market Size (2018-2029) & (USD Million)
Figure 4. World Transarterial Chemoembolization (TACE) Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Transarterial Chemoembolization (TACE) Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Transarterial Chemoembolization (TACE) Revenue (2018-2029) & (USD Million)
Figure 13. Transarterial Chemoembolization (TACE) Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 16. World Transarterial Chemoembolization (TACE) Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 18. China Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 23. India Transarterial Chemoembolization (TACE) Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Transarterial Chemoembolization (TACE) by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Transarterial Chemoembolization (TACE) Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Transarterial Chemoembolization (TACE) Markets in 2022
Figure 27. United States VS China: Transarterial Chemoembolization (TACE) Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Transarterial Chemoembolization (TACE) Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Transarterial Chemoembolization (TACE) Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Transarterial Chemoembolization (TACE) Market Size Market Share by Type in 2022
Figure 31. Chemotherapeutic Agents
Figure 32. Radio Therapeutic Agents
Figure 33. Drug-eluting Particles
Figure 34. Others
Figure 35. World Transarterial Chemoembolization (TACE) Market Size Market Share by Type (2018-2029)
Figure 36. World Transarterial Chemoembolization (TACE) Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 37. World Transarterial Chemoembolization (TACE) Market Size Market Share by Application in 2022
Figure 38. Hospitals
Figure 39. Clinics
Figure 40. Cancer Research Centers
Figure 41. Transarterial Chemoembolization (TACE) Industrial Chain
Figure 42. Methodology
Figure 43. Research Process and Data Source
